Ovarian hyperstimulation in premenopausal women during adjuvant tamoxifen treatment for endocrine‑dependent breast cancer: A report of two cases

Madeddu,Clelia; Gramignano,Giulia; Kotsonis,Paraskevas; Paribello,Francesco; Macciò,Antonio

doi:10.3892/ol.2014.2319

Ovarian hyperstimulation in premenopausal women during adjuvant tamoxifen treatment for endocrine‑dependent breast cancer: A report of two cases

Authors:
- Clelia Madeddu
- Giulia Gramignano
- Paraskevas Kotsonis
- Francesco Paribello
- Antonio Macciò
View Affiliations

Affiliations: Department of Medical Science ‘Mario Aresu’, University of Cagliari, Monserrato, Cagliari I‑09042, Italy, Medical Oncology Unit, ‘N.S. Bonaria’ Hospital, San Gavino I‑09037, Italy, Department of Obstetrics and Gynaecology, Sirai Hospital, Carbonia I‑09013, Italy, Department of Public Health, University of Cagliari, Monserrato, Cagliari I‑09042, Italy, Department of Gynecologic Oncology, ‘A. Businco’ Hospital, Regional Referral Center for Cancer Disease, Monserrato, Cagliari I‑09121, Italy
Published online on: July 4, 2014 https://doi.org/10.3892/ol.2014.2319
Pages: 1279-1282

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Adjuvant endocrine therapy is an integral component of care for endocrine‑dependent breast cancer. The aim of this type of therapy is to counteract the production and the action of estrogens. The ovary is the primary site of estrogen production in premenopausal women, whereas, in postmenopausal women, the main source of estrogens is adipose tissue. Therefore, ovarian function suppression is an effective adjuvant strategy in premenopausal estrogen‑dependent breast cancer. Similarly, the inhibition of estrogen action at the receptor site by tamoxifen has proven to be effective. To date, international consensus statements recommend tamoxifen (20 mg/day) for five years as the standard adjuvant endocrine therapy for premenopausal women. It should be noted that tamoxifen is a potent inducer of ovarian function and consequent hyperestrogenism in premenopausal women. In the present study, we report two cases of ovarian cyst formation with very high estrogen levels and endometrial hyperplasia during the administration of tamoxifen alone as adjuvant treatment for estrogen receptor‑positive breast cancer in premenopausal women. These cases suggest that in young premenopausal patients with estrogen‑dependent breast cancer, ovarian suppression is an essential prerequisite for an adjuvant endocrine therapy with tamoxifen. In this context, luteinizing hormone‑releasing hormone agonist treatment by suppressing effective ovarian function may lead to a hypoestrogenic status that may positively impact breast cancer prognosis and prevent the effects of tamoxifen at the gynecological level. It is important to reconsider the action of tamoxifen on ovarian function and include these specific effects of tamoxifen in the informed consent of premenopausal patients who are candidates for tamoxifen alone as adjuvant endocrine treatment.

View Figures

View References

1	Jankowitz RC, McGuire KP and Davidson NE: Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer. Breast. 22(Suppl 2): S165–S170. 2013.
2	Senkus E, Kyriakides S, Penault-Llorca F, Poortmans P, Thompson A, Zackrisson S and Cardoso F; ESMO Guidelines Working Group. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 24(Suppl 6): vi7–vi23. 2013.
3	Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B and Senn HJ; Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 24:2206–2223. 2013.
4	Goel S, Sharma R, Hamilton A and Beith J: LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Cochrane Database Syst Rev. 2009.CD0045622009.
5	Davidson NE, O’Neill AM, Vukov AM, Osborne CK, Martino S, White DR and Abeloff MD: Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol. 23:5973–5982. 2005.
6	Higgins MJ and Davidson NE: What is the current status of ovarian suppression/ablation in women with premenopausal early-stage breast cancer? Curr Oncol Rep. 11:45–50. 2009.
7	Del Mastro L, Levaggi A, Giraudi S and Pronzato P: Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients: current role and future perspectives. Cancer Treat Rev. 37:208–211. 2011.
8	Mourits MJ, de Vries EG, Willemse PH, ten Hoor KA, Hollema H, Sluiter WJ, de Bruijn HW and van der Zee AG: Ovarian cysts in women receiving tamoxifen for breast cancer. Br J Cancer. 79:1761–1764. 1999.
9	Jordan VC, Fritz NF, Langan-Fahey S, Thompson M and Tormey DC: Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. J Natl Cancer Inst. 83:1488–1489. 1991.
10	Zarbo G, Caruso G, Zammitti M, Caruso S and Zarbo R: The effects of tamoxifen therapy on the endometrium. Eur J Gynaecol Oncol. 21:86–88. 2000.
11	American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG committee opinion: No. 336: Tamoxifen and uterine cancer. Obstet Gynecol. 107:1475–1478. 2006.
12	Cohen I, Figer A, Tepper R, Shapira J, Altaras MM, Yiagel D and Beyth Y: Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: comparison between tamoxifen-treated and nontreated breast cancer patients. Gynecol Oncol. 72:202–207. 1999.
13	Shushan A, Peretz T, Uziely B, Lewin A and Mor-Yosef S: Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer. Am J Obstet Gynecol. 174:141–144. 1996.
14	Shushan A, Peretz T and Mor-Yosef S: Therapeutic approach to ovarian cysts in tamoxifen-treated women with breast cancer. Int J Gynecol Obstet. 52:249–253. 1996.
15	Cohen I, Tepper R, Figer A, Flex D, Shapira J and Beyth Y: Successful co-treatment with LHRH-agonist for ovarian over-stimulation and cystic formation in premenopausal tamoxifen exposure. Breast Cancer Res Treat. 55:119–125. 1999.
16	Shulman A, Cohen I, Altaras MM, Maymon R, Ben-Nun I, Tepper R and Beyth Y: Ovarian cyst formation in two pre-menopausal patients treated with tamoxifen for breast cancer. Hum Reprod. 9:1427–1429. 1994.
17	Turan C, Unal O, Dansuk R, Guzelmeric K, Cengizoglu B and Esim E: Successful management of an ovarian enlargement resembling ovarian hyperstimulation in a premenopausal breast cancer patient receiving tamoxifen with cotreatment of GnRH-agonist. Eur J Obstet Gynecol Reprod Biol. 97:105–107. 2001.
18	Bao T and Davidson NE: Adjuvant endocrine therapy for premenopausal women with early breast cancer. Breast Cancer Res. 9:1152007.
19	Berliere M, Duhoux FP, Dalenc F, Baurain JF, Dellevigne L, Galant C, Van Maanen A, Piette P and Machiels JP: Tamoxifen and ovarian function. PLoS One. 8:e666162013.
20	Groom GV and Griffiths K: Effect of the anti-oestrogen tamoxifen on plasma levels of luteinizing hormone, follicle-stimulating hormone, prolactin, oestradiol and progesterone in normal pre-menopausal women. J Endocrinol. 70:421–428. 1976.
21	Goldhirsch A, Gelber RD, Yothers G, Gray RJ, Green S, Bryant J, Gelber S, Castiglione-Gertsch M and Coates AS: Adjuvant therapy for very young women with breast cancer: need for tailored treatments. J Natl Cancer Inst Monogr. 30:44–51. 2001.
22	Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 365:1687–1717. 2005.
23	LHRH-agonists in Early Breast Cancer Overview Group. Cuzick J, Ambroisine L, et al: Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet. 369:1711–1723. 2007.
24	Petrek JA, Naughton MJ, Case LD, Paskett ED, Naftalis EZ, Singletary SE and Sukumvanich P: Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol. 24:1045–1051. 2006.
25	Neri F and Maggino T: Surveillance of endometrial pathologies, especially for endometrial cancer, of breast cancer patients under tamoxifen treatment. Eur J Gynaecol Oncol. 30:357–360. 2009.
26	Yang H, Zong X, Yu Y, Shao G, Zhang L, Qian C, Bian Y, Xu X, Sun W, Meng X, Ding X, Chen D, Zou D, Xie S, Zheng Y, Zhang J, He X, Sun C, Yu X and Ni J: Combined effects of goserelin and tamoxifen on estradiol level, breast density, and endometrial thickness in premenopausal and perimenopausal women with early-stage hormone receptor-positive breast cancer: a randomised controlled clinical trial. Br J Cancer. 109:582–588. 2013.